March 15, 2016

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Ref: Your email dated March 15, 2016, enclosing therewith, letter bearing Ref. No. NSE/CM/Surveillance/6198 dated March 15, 2016, requesting confirmation/ information on published news.

In connection with the above, we wish to state that the US FDA inspected Lupin's Goa facility last week and cited 9 observations. The observations are on aspects such as inadequacy and adherence to SOPs. We are in the midst of putting together a response to address the US FDA's Observations.

We wish to add that the Company has no control over the movement of price of the scrip as the same is determined by market forces.

We hope the above answers your queries.

Thanking you,

Yours faithfully,
For LUPIN LIMITED

R. V. SATAM
COMPANY SECRETARY & COMPLIANCE OFFICER

Encl.: a/a